Category: Press Releases

Posted on

RapidPulse se lance avec un financement de série A de 15 millions de dollars pour le traitement des accidents vasculaires cérébraux ischémiques

Des vétéranes de l’industrie rejoignent l’équipe pour soutenir le développement d’un nouveau système d’aspiration cyclique pour les accidents vasculaires cérébraux ischémiques

MIAMI, 23 juin 2021 (GLOBE NEWSWIRE) — RapidPulse, Inc., une société privée spécialisée dans les dispositifs médicaux qui développe un nouveau système d’aspiration pour traiter les accidents vasculaires cérébraux ischémiques, a annoncé aujourd’hui la clôture d’un financement de série A de 15 millions de dollars. Le financement a été mené par Santé Ventures qui a été rejointe par Epidarex Capital, Hatteras Venture Partners, Broadview Ventures et Syntheon. RapidPulse prévoit d’utiliser les recettes pour faire progresser son système d’aspiration cyclique RapidPulse™ grâce à une évaluation clinique élargie et pour construire sa plateforme de cathéters brevetés.

Le système RapidPulse™ a été développé par Syntheon, un incubateur de dispositifs médicaux axé sur le développement de dispositifs médicaux de nouvelle génération. Ses différents produits, commercialisés par les sociétés de dispositifs médicaux les plus importantes et les plus réputées au monde, ont traité plus de 50 millions de patients dans le monde entier dans des applications allant de la chirurgie laparoscopique au domaine cardiovasculaire, en passant par l’endoscopie flexible. Syntheon a émis plus de 200 brevets depuis sa création il y a plus de 20 ans.

« Nous sommes ravis d’avoir conclu un partenariat avec un syndicat d’investisseurs exceptionnel pour faire progresser notre technologie RapidPulse™ en clinique », a déclaré Sean McBrayer, PDG de Syntheon, qui occupera également le poste de PDG initial de RapidPulse. « Les accidents vasculaires cérébraux sont la deuxième cause de décès et la troisième cause de handicap dans le monde, et la moindre minute compte pour améliorer ces résultats. Cet investissement nous aidera à étendre nos résultats cliniques et à nous diriger vers l’approbation réglementaire aux États-Unis. »

Heather Harries et Cynthia Yang, vétéranes de l’industrie, rejoindront l’équipe. Mme Harries a le plus récemment occupé le poste de directrice générale de l’activité aortique de Terumo et dirigera le développement des produits et les opérations de RapidPulse. Mme Yang dirigera le développement clinique de la société, après avoir récemment travaillé au sein de la division neurovasculaire de Medtronic.

Dennis McWilliams, associé chez Santé Ventures, a ajouté : « Heather et Cynthia apportent une expertise sectorielle exceptionnelle à l’équipe de RapidPulse, et complèteront l’expérience significative de développement en ingénierie de Syntheon. RapidPulse est une opportunité de plateforme révolutionnaire dans le domaine neurovasculaire, et a le potentiel d’améliorer de manière significative les résultats pour les patients atteints d’accidents vasculaires cérébraux ischémiques. »

À PROPOS DE RAPIDPULSE

RapidPulse, Inc. est une société privée spécialisée dans les dispositifs médicaux qui développe des produits vasculaires mini-invasifs pour les accidents vasculaires cérébraux ischémiques. La société fait progresser le développement du système d’aspiration cyclique RapidPulse™, qui comprend une nouvelle pompe d’aspiration pour permettre un retrait rapide et constant des caillots sanguins du cerveau. RapidPulse est une spin-out de Syntheon LLC., un incubateur de dispositifs médicaux dédié au développement de produits innovants dans l’industrie des dispositifs médicaux. Pour de plus amples informations, consultez le site www.rapidpulsemed.com.

À PROPOS DE SANTÉ VENTURES

Santé Ventures est une société d’investissement dans les sciences de la vie qui investit dans des sociétés en phase initiale dans les services de santé numériques, de biotechnologie et de dispositifs médicaux. Nous collaborons avec des entrepreneurs pour créer des entreprises ayant un impact, y compris Claret Medical (qui fait désormais partie de Boston Scientific), TVA Medical (Becton Dickinson), Millipede Medical (Boston Scientific) et Molecular Templates (NASDAQ : MTEM). Fondée en 2006, Santé dispose de juste un peu moins d’un milliard de dollars d’actifs sous gestion et possède des bureaux à Austin, au Texas, et Boston, dans le Massachusetts. Pour tout complément d’information, veuillez consulter le site sante.com.

À PROPOS D’EPIDAREX CAPITAL

Epidarex Capital est une société transatlantique de capital-risque qui construit des sociétés exceptionnelles dans le domaine des sciences de la vie dans des pôles émergents aux États-Unis et au Royaume-Uni. L’équipe expérimentée d’investisseurs en phase initiale d’Epidarex s’associe aux entrepreneurs et aux institutions de recherche de premier plan pour transformer la science de classe mondiale en produits hautement innovants répondant aux principaux besoins non satisfaits dans le domaine des soins de santé mondiaux. Pour de plus amples informations, veuillez consulter le site www.epidarex.com

À PROPOS DE HATTERAS VENTURE PARTNERS

Fondée en 2000 et basée à Durham, en Caroline du Nord, Hatteras Venture Partners est une société de capital-risque axée sur l’investissement dans les soins de santé à un stade précoce et d’amorçage. Grâce à six fonds et à plus de 600 millions de dollars sous gestion, la société a investi dans la science de pointe et l’esprit entrepreneurial dans les domaines de la biopharmacie, des dispositifs médicaux, des diagnostics, des technologies informatiques de la santé et dans les opportunités connexes de la médecine humaine. Pour en savoir plus, veuillez consulter le site www.hatterasvp.com.

À PROPOS DE BROADVIEW VENTURES

Fondée en 2008, Broadview Ventures est une organisation d’investissement axée sur sa mission. L’objectif principal de Broadview est d’améliorer la santé humaine dans les domaines des maladies cardiovasculaires et des accidents vasculaires cérébraux grâce à des investissements dans des entreprises en phase initiale qui développent des thérapies, des dispositifs et des diagnostics innovants. Pour plus d’informations sur Broadview Ventures, rendez-vous sur broadviewventures.org.

CONTACT AUPRÈS DES MÉDIAS :

Sean McBrayer, info@rapidpulsemed.com, 305-266-3388

Posted on

Prix UNCA 2021 concours de la meilleure couverture mediatique de l’ONU et de ses agences

Remise des prix en décembre 2021 (date à définir) à New York au Gala de l’UNCA sous la présidence d’honneur du Secrétaire général António Guterres

NEW YORK, 24 juin 2021 /PRNewswire/ — L’association des Correspondants de presse des Nations Unies (UNCA) invite les médias du monde entier — presse écrite, télévisuelle et radio, presse en ligne — à participer au 25e concours annuel de la meilleure couverture de la pandémie de Covid-19, du changement climatique, et de l’ONU, de ses agences et de ses opérations de terrain.

United Nations Correspondents Association Logo

Alors que la cérémonie du 25e anniversaire n’a pu se tenir en 2020 à cause de la pandémie, l’association des Correspondants de presse des Nations Unies renouera en décembre avec son évènement annuel afin d’honorer l’excellence en journalisme dans le monde.

La date limite de réception des formulaires en ligne et des travaux soumis au jury est le 15 septembre 2021.

Le concours est ouvert aux journalistes du monde entier.

Voici les prix qui seront remis:

  1. Prix Elizabeth Neuffer, parrainé par la fondation Alexander Bodini. Le prix est pour la couverture de la pandémie de Covid-19 par la presse écrite (dont les médias en ligne) et audiovisuelle (TV et radio).
  2. Prix Mondial du Prince Albert II de Monaco et de l’Association des correspondants de presse de l’ONU pour les changements climatiques. Il récompense la couverture par la presse écrite (dont les médias en ligne) et audiovisuelle (TV et radio), du changement climatique, de la biodiversité et de la gestion des ressources en eau.
  3. Prix Ricardo Ortega, parrainé par l’Alliance des civilisations des Nations Unies, pour la couverture de l’ONU et de ses agences, par la presse écrite (dont les médias en ligne) et audiovisuelle (TV et radio).

INFORMATION IMPORTANTE POUR LES CANDIDATS:

La couverture souhaitée de l’ONU et de ses agences est précisée dans chaque catégorie. Le Comité accepte tous les sujets, en particulier ceux concernant les Objectifs du développement durable pour 2030, les opérations de maintien de la paix et la non-prolifération, y compris l’élimination des armes nucléaires, chimiques et bactériologiques.

Les travaux présentés (articles de presse écrite ou sur internet, programmes de radio ou de télévision) doivent avoir été publiés entre septembre 2019 et août 2021.

Le jury privilégiera les travaux démontrant perspicacité et originalité et prendra en considération le courage et les qualités d’investigation et d’écriture des journalistes. La participations de médias de pays en développement est particulièrement encouragée.

Les travaux peuvent être présentés dans n’importe laquelle des langues officielles de l’ONU (anglais, français, arabe, chinois, espagnol, russe). Une transcription écrite en anglais ou français est recommandée pour faciliter la sélection.

Chaque candidat peut soumettre des travaux pour DEUX prix AU MAXIMUM, avec un maximum de deux (2) travaux pour chaque prix.

  • Il faut envoyer vos travaux par voie électronique en incluant le lien ou en téléchargeant tous les documents directement sur le formulaire d’inscription.

COMMENT FAIRE ACTE DE CANDIDATURE:

Les travaux sont soumis en remplissant le formulaire en ligne.

Sur la première page, veuillez compléter vos informations personnelles et télécharger votre photo.

La page suivante est l’endroit où vous soumettrez votre travail par voie électronique en téléchargeant des liens Web et/ou des fichiers directement sur le formulaire d’inscription.

FORMULAIRE D’INSCRIPTION
http://unca.com/unca-awards-call-for-submissions-form/

**Les envois électroniques sont obligatoires**

Votre candidature doit être reçue au plus tard le 15 septembre 2021

Pour toute question au sujet du concours, veuillez contacter:
le Bureau de l’UNCA au 1-212-963-7137
Ou envoyer un email à l’adresse suivante: uncaawards@unca.com

Comité du concours UNCA:

UNCA Awards Committee : Valeria Robecco (UNCA President), Giampaolo Pioli (Awards Chairman), Tuyet Nguyen (Awards Selections Coordinator), Sherwin Bryce-Pease (UNCA Executive Member), Edith Lederer (UNCA Executive Member), Linda Fasulo (UNCA Executive Member)

Logo – https://mma.prnewswire.com/media/1550296/United_Nations_Correspondents_Association_Logo.jpg

Posted on

2021 UN Correspondents Association Awards for Best Journalistic Coverage of the United Nations and UN Agencies

WINNERS WILL BE HONORED BY THE UN SECRETARY-GENERAL H.E. ANTÓNIO GUTERRES DECEMBER 2021 (DATE TBD) IN NEW YORK

NEW YORK, June 24, 2021 /PRNewswire/ — The United Nations Correspondents Association (UNCA) invites media worldwide to submit entries for its 25th anniversary of the UNCA Awards for best print, broadcast (TV & Radio) and online, web-based media coverage of COVID-19, climate change and the United Nations, UN agencies and field operations.

United Nations Correspondents Association Logo

While the UNCA Awards 25th anniversary was put on hold in 2020 due to the coronavirus pandemic, this year the UN Correspondents Association will return to hosting the annual event in December, honoring excellence in journalism around the globe.

Deadline for submissions is September 15, 2021.

The awards are open to all journalists anywhere in the world.

The Awards are:

  1. The Elizabeth Neuffer Memorial Prize for coverage of the COVID-19 pandemic, sponsored by the Alexander Bodini Foundation. The prize is for print (including online media) and broadcast media (TV & Radio).
  2. The Prince Albert II of Monaco and UNCA Global Prize for Coverage of Climate Change. The prize is for print (including online media) and broadcast media (TV & Radio).
  3. The Ricardo Ortega Memorial Prize for coverage of the United Nations, UN agencies and field operations, sponsored by the United Nations Alliance of Civilizations. The prize is for print (including online media) and broadcast media (TV & Radio)

IMPORTANT INFORMATION FOR APPLICANTS:

Work in print, broadcast (TV & Radio) and online coverage must be published between September 2019 and August 2021.

The judges will look for entries with impact, insight, and originality, and will consider the courage and investigative and reporting skills of the journalists. Entries from the developing world media are particularly welcome.

Entries can be submitted in any of the official UN languages (English, French, Arabic, Chinese, Spanish, and Russian), however a written transcript in English or French is necessary to facilitate the judging process.

Each candidate can submit to no more than two (2) prize categories, with a maximum of two (2) stories in each. Joint entries are accepted.

Electronic files and web links uploaded to the online Entry Form are required.

HOW TO SUBMIT YOUR ENTRY:

Entries are submitted online by completing the UNCA Awards Entry Form.

On the first page, please complete your personal information and upload your photo.
The following page is where you will submit your work electronically by uploading web links and/or files directly to the Entry Form.

** Electronic entries are mandatory **

All entries must be received by September 15th, 2021

For Questions regarding UNCA Awards & entries please contact:
The UNCA Office, 1-212-963-7137.
Or send an email to uncaawards@unca.com

CLICK ON THE ENTRY FORM BELOW TO GET STARTED:
 ENTRY FORM
http://unca.com/unca-awards-call-for-submissions-form/

UNCA Awards Committee: Valeria Robecco (UNCA President), Giampaolo Pioli (Awards Chairman), Tuyet Nguyen (Awards Selections Coordinator), Sherwin Bryce-Pease (UNCA Executive Member), Edith Lederer (UNCA Executive Member), Linda Fasulo (UNCA Executive Member)

Logo – https://mma.prnewswire.com/media/1550296/United_Nations_Correspondents_Association_Logo.jpg

Posted on

Graduate Management Admission Council Welcomes New Members to the Board

New additions reflect the diverse, global perspective of the business school community

RESTON, Va., June 23, 2021 (GLOBE NEWSWIRE) — The Graduate Management Admission Council™ (GMAC™), a global association of leading graduate business schools, today announced the addition of four new members to its board of directors. Katy Montgomery, Associate Dean, Degree Programmes, INSEAD; François Ortalo-Magné, Dean, London Business School; and Giuseppe Soda, Dean, SDA Bocconi School of Management, Bocconi University, will begin their terms on July 1. In addition, Yuan Ding, Vice President and Dean of China Europe International Business School (CEIBS), was appointed as a board director in January this year to fill the seat vacated by Enase Okonedo of the Pan-Atlantic University.

“GMAC’s new board of directors represent leading business schools with campuses located in 10 countries across Europe, Asia, North America, Africa, and the Middle East,” said Sangeet Chowfla, president and CEO of GMAC. “As student mobility returns and regains in the post-pandemic world, I look forward to working alongside this diverse group of leaders ― and the rest of the GMAC board ― to continue to advance GMAC’s vision to ensure that all talented individuals can benefit from the best business education for them.”

New GMAC Board Members

Yuan Ding, Vice President and Dean, Cathay Capital Chair in Accounting, CEIBS

Yuan Ding is Vice President and Dean and the Cathay Capital Chair Professor in Accounting at CEIBS, where he has been honored three times with the CEIBS Teaching Excellence Award. Prior to joining CEIBS, he was a tenured faculty member of the HEC School of Management, Paris, France. He is a member of the European Accounting Association, French Accounting Association and American Accounting Association. He holds a PhD in Accounting from the Institute of Enterprises Administration at the University Montesquieu Bordeaux IV, France, as well as a Master’s in Enterprises Administration from the University of Poitiers, France. Ding is the author of multiple books on financial reporting and his research appears in leading academic journals.

Katy Montgomery, Associate Dean, Degree Programmes, INSEAD

As the INSEAD Associate Dean of Degree Programmes, Montgomery is responsible for the commercial leadership of the INSEAD Degree Programme portfolio across four campuses: Fontainebleau, Singapore, Abu Dhabi, and San Francisco. Her functional responsibilities include strategy, marketing, sales, admissions, financial aid and scholarships, programme operations, student life, psychological services, and career services. Prior to joining INSEAD, she served as Associate Dean of Student Development at Johns Hopkins Carey Business School. Montgomery holds a degree in Political Science from Loyola University New Orleans and a Juris Doctor degree from Georgetown University Law Center.

François Ortalo-Magné, Dean, London Business School

François Ortalo-Magné is the ninth Dean of London Business School (LBS), a position he has held since August 2017. He is leading a strategy focused on (1) academic research and its impact, (2) learning innovations and alumni engagement and (3) inclusion, striving for gender parity and greater socio-economic and ethnic diversity. Since taking up the role, Ortalo-Magné has led the relaunch of the LBS brand, the growth of degree programmes and a significant increase in philanthropic support for scholarships. His research on the economics of land and housing markets has been published in leading academic journals. He has built on his research and leadership experiences to advise a broad range of private, governmental and multi-lateral organisations and share his insights in leading media outlets and at conferences around the world. Prior to his appointment, Ortalo-Magné was the Albert O. Nicholas Dean and Robert E. Wangard Professor of Real Estate at the Wisconsin School of Business. His first academic appointment was at the London School of Economics.

Giuseppe Soda, Dean, SDA Bocconi School of Management, Bocconi University

Giuseppe “Beppe” Soda is the Dean of SDA Bocconi School of Management and Full Professor of Organization Theory and Network Analysis at Bocconi University. Before becoming Dean in 2016, his roles have included serving as the Associate Dean for Research (2007-2013), Director of the Department of Management and Technology (2013-2016) and Head of Organization and HRM Department (2001-2006). He is also serving EFMD as member of the EQUIS Accreditation Board. Soda’s research investigates the performance consequences of the interplay between organizational architectures and organizational networks and his work has been published in top academic management journals.

Besides the aforementioned newly elected board members, Martin Boehm, Professor of Marketing and former Dean of IE Business School and soon the new Rector of EBS Universität für Wirtschaft und Recht, and Themin Suwardy, Dean of Postgraduate Professional Programmes, Singapore Management University, were re-elected for a second term.

GMAC also recognizes its outgoing board members, Leila Guerra, Vice Dean (Education) of Imperial College Business School, and Peter Tufano, Peter Moores Dean and Professor of Finance of Saïd Business School, University of Oxford. GMAC thanks them for their service in the past nearly four years to our organization and contributions to the graduate management education community.

About GMAC™

The Graduate Management Admission Council™ (GMAC™) is a mission-driven association of leading graduate business schools worldwide. Founded in 1953, GMAC creates solutions and experiences that enable business schools and candidates to better discover, evaluate, and connect with each other.

GMAC provides world-class research, industry conferences, recruiting tools, and assessments for the graduate management education industry, as well as tools, resources, events, and services that help guide candidates through their higher education journey. Owned and administered by GMAC, the Graduate Management Admission Test™ (GMAT™) exam is the most widely used graduate business school assessment.

GMAC also owns and administers the NMAT by GMAC™ (NMAT™) exam and the Executive Assessment (EA). More than 7 million candidates on their business master’s or MBA journey visited GMAC’s mba.com last year to explore business school options, prepare and register for exams, and get advice on the admissions process. BusinessBecause and The MBA Tour are subsidiaries of GMAC, a global organization with offices in China, India, the United Kingdom, and the United States.

To learn more about our work, please visit www.gmac.com.

Media Contact:

Teresa Hsu
Sr. Manager, Media Relations
202-390-4180 (mobile)
thsu@gmac.com

Posted on

RapidPulse Launches With $15 Million Series A Financing for Ischemic Stroke Therapy

Industry Veterans Join Team to Support the Development of Novel Cyclic Aspiration System for Ischemic Stroke

MIAMI, June 23, 2021 (GLOBE NEWSWIRE) — RapidPulse, Inc., a privately-held medical device company developing a novel aspiration system to treat ischemic stroke, today announced the closing of a $15 million Series A financing. The financing was led by Santé Ventures who was joined by Epidarex Capital, Hatteras Venture Partners, Broadview Ventures, and Syntheon. RapidPulse plans to use the proceeds to advance its RapidPulse™ Cyclic Aspiration System through expanded clinical evaluation and build out its platform of proprietary catheters.

The RapidPulse™ system was developed by Syntheon, a medical device incubator focused on developing next generation medical devices. Their various products, commercialized by the largest and most trusted medical device companies in the world, have treated over 50 million patients globally in applications ranging from laparoscopic surgery, cardiovascular, and flexible endoscopy. Syntheon has over 200 issued patents since its inception over 20 years ago.

“We are pleased to have partnered with an outstanding investor syndicate to move our RapidPulse™ technology forward in the clinic,” said Sean McBrayer, CEO of Syntheon who will also serve as initial CEO of RapidPulse. “Stroke is the second leading cause of death and the third leading cause of disability worldwide, and minutes matter in improving these outcomes. This investment will help us expand our clinical results and move towards regulatory approval in the United States.”

Joining the team are industry veterans Heather Harries and Cynthia Yang. Heather most recently served as General Manager for Terumo’s aortic business and will lead product development and operations for RapidPulse. Cynthia will lead clinical development for the company, after most recently working in the neurovascular division of Medtronic.

Dennis McWilliams, partner at Santé Ventures, added, “Heather and Cynthia bring exceptional domain expertise to the team at RapidPulse, and will complement the significant engineering development experience at Syntheon. RapidPulse is a disruptive platform opportunity in neurovascular, and has the potential to significantly improve patient outcomes for ischemic stroke patients.”

ABOUT RAPIDPULSE

RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry. Visit www.rapidpulsemed.com for more information.

ABOUT SANTÉ VENTURES

Santé Ventures is a life sciences investment firm that invests in early-stage companies in medical device, biotechnology, and digitally enabled health services. We partner with entrepreneurs to build impactful companies, including Claret Medical (now part of Boston Scientific), TVA Medical (Becton Dickinson), Millipede Medical (Boston Scientific), and Molecular Templates (NASDAQ: MTEM). Founded in 2006, Santé has just under $1 billion in assets under management, and has offices in Austin, TX and Boston, MA. For more information, please visit sante.com.

ABOUT EPIDAREX CAPITAL

Epidarex Capital is a transatlantic venture capital firm that builds exceptional life science companies in emerging hubs in the US and UK. Epidarex’s experienced team of early-stage investors partner with entrepreneurs and leading research institutions to transform world-class science into highly innovative products addressing major unmet needs in global healthcare. For more information, please visit www.epidarex.com

ABOUT HATTERAS VENTURE PARTNERS

Founded in 2000 and based in Durham, NC, Hatteras Venture Partners is a venture capital firm with a focus on seed and early stage healthcare investing. Through six funds and over $600 million under management, the firm has invested in breakthrough science and entrepreneurial grit in the areas of biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related opportunities in human medicine. To learn more, please visit www.hatterasvp.com.

ABOUT BROADVIEW VENTURES

Founded in 2008, Broadview Ventures is a mission-driven investment organization. Broadview’s primary goal is to improve human health in the areas of cardiovascular disease and stroke through investments in early stage companies developing innovative therapeutics, devices, and diagnostics. For more information about Broadview Ventures, visit broadviewventures.org.

MEDIA CONTACT:

Sean McBrayer, info@rapidpulsemed.com, 305-266-3388

Posted on

Conformis, Inc. Announces Exclusive Distribution Agreement in China

New Agreement expands Conformis’ global reach and brings patient-specific knee replacement systems to the largest market in the Asia-Pacific region

BILLERICA, Mass., June 23, 2021 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS) today announced the execution of an agreement to enter the Asia-Pacific market through an exclusive distribution relationship with XR Medical Group (Hong Kong) Limited (XR Medical).

Under the distribution agreement, XR Medical will have exclusive rights for the sale, marketing, and distribution of Conformis’ patient-specific iTotal® CR & PS total knee replacement systems, iTotal® CR & PS patella devices, and iUni® and iDuo® partial knee replacement systems. Other products, such as Conformis’ recently approved Identity Imprint™ knee system and its hip portfolio of products, may be added in the future.

XR Medical’s sales team will provide sales and support exclusively to top-tier facilities in Hainan’s Boao Lecheng International Medical Tourism Pilot Zone (Pilot Zone) on behalf of Conformis. The region is a major center of medical tourism for dozens of countries.

“This distribution agreement is another example of progress as we execute our overall growth strategy. We are confident that our unique product portfolio will serve to accelerate Conformis’ international growth. And we are pleased to partner with XR Medical, which has an impressive track record of success in China,” said Mark Augusti, President and CEO of Conformis. “What is particularly attractive about XR Medical is its strong performance in the Pilot Zone. With access to patients visiting the region for treatment, this creates an opportunity to introduce a broad audience to the clinical benefits of Conformis technology. We believe that starting in the Pilot Zone positions us well and we anticipate that this relationship will serve as a model for future expansion opportunities in mainland China.”

The Pilot Zone is located on Hainan, a large island off China’s southern coast. It was established in 2019 to attract affluent Chinese citizens who might otherwise go abroad for their medical care. This region of China has developed top-level medical treatment facilities in a popular destination. Currently, medical tourists from dozens of countries, including those in Southeast Asia, are permitted to visit Hainan for a 30-day stay without visas.

The global market for knee joint reconstruction is projected at more than $9 billion. Of this total, the knee joint reconstruction market in the Asia-Pacific region is currently estimated to exceed $1.7 billion. Fortune Business Insights predicts a high growth rate for knee replacements in the region due to the combination of the increased prevalence of knee disorders, booming medical tourism, increased disposable incomes, and improved healthcare infrastructure.

About Conformis, Inc.

Conformis is a medical technology company that uses its proprietary iFit® Image-to-Implant® technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit and conform to each patient’s unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and standard implants, along with single-use instruments delivered to hospitals and ambulatory surgical centers. In clinical studies, the Conformis iTotal® CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.

For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at http://ir.conformis.com.

Cautionary Statement Regarding Forward-Looking Statements

Statements in this press release about our future expectations, plans and prospects, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar expressions, constitute forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. You should not place undue reliance on our forward-looking statements. Actual results could differ materially from the projections disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks and uncertainties described in the “Risk Factors” sections of our public filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

Source: Conformis, Inc.

Media Contact:
Investor Relations
ir@conformis.com
(781) 374-5598
Proudly powered by WordPress